Abstract:Accumulating evidence suggests that stress-dose corticosteroids impair fear memory in animals and humans. Corticosteroid treatment after critical illness is seen as a potential psychotropic medication by which to prevent posttraumatic stress disorder. However, individual difference in the responsiveness to stress (i.e., stress reactivity) is a factor that modulates the efficacy of corticosteroids. To understand the contribution of fear reactivity to the effect of post-stress corticosterone, male Sprague-Dawley rats were subjected to classical tone-cued fear conditioning and separated into high and low reactivity (HR and LR, respectively) responder groups based on their levels of freezing during conditioning. The HR rats showed significantly higher fear responses than the LR rats during conditioning as assessed by freezing behavior. At two intervals, 30 min and 48 hr later, the HR rats still displayed more pronounced conditioned responses to cued stimuli compared with the LR rats. Moreover, in contrast to the LR rats, the enhanced fear response in the HR rats was difficult to attenuate by post-training high-dose corticosterone. These results suggest that fear reactivity results in stronger fear memory, and that it is difficult to disrupt this strong fear memory in the HR phenotype using monotherapy. However, the strong fear memory in the HR rats was impaired by concurrent intramedial prefrontal cortex infusion of a high dose of the dopamine D-1 receptor antagonist SCH 23390 and systemic administration of corticosterone. SCH 23390 and corticosterone alone did not decrease freezing levels in the HR rats. The fear impairment induced by SCH 23390 combined with corticosterone was not attributable to the effect of these drugs on locomotor activity. This effect was not found with administration of the D-2 antagonist eticlopride combined with corticosterone. Our findings demonstrate that the conditioned fear memory in individuals with high stress reactivity is difficult to disrupt using monotherapy, but that combined pharmacotherapy may be useful for treating intervention-resistant fear.

Antagonizing Corticotropin-Releasing Factor in the Central Nucleus of the Amygdala Attenuates Fear-Induced Reductions in Sleep but Not Freezing

Corticotropin Releasing Factor (CRF) Modulates Fear-Induced Alterations in Sleep in Mice

Suppression of preoptic sleep-regulatory neuronal activity during corticotropin-releasing factor-induced sleep disturbance

Cell-type specific deletion of GABA(A)α1 in corticotropin-releasing factor-containing neurons enhances anxiety and disrupts fear extinction

Effects of corticotropin releasing factor (CRF) on sleep and body temperature following controllable footshock stress in mice.

Fear-conditioned suppression of REM sleep: relationship to Fos expression patterns in limbic and brainstem regions in BALB/cJ mice.

Regulation of Cued Fear Expression via Corticotropin-Releasing-Factor Neurons in the Ventral Anteromedial Thalamic Nucleus

Predicting Aversive Events And Terminating Fear In The Mouse Anterior Cingulate Cortex During Trace Fear Conditioning

Contextual Fear Extinction Ameliorates Sleep Disturbances Found Following Fear Conditioning in Rats.

Gabaergic Antagonism of the Central Nucleus of the Amygdala Attenuates Reductions in Rapid Eye Movement Sleep after Inescapable Footshock Stress

Corticotropin-Releasing Factor and Defensive Withdrawal: Inhibition of Monoamine Oxidase Prevents Habituation to Chronic Stress

The Basolateral Amygdala Mediates the Role of Rapid Eye Movement Sleep in Integrating Fear Memory Responses

Corticotropin-releasing factor receptor type 1 and 2 mRNA expression in the rat anterior pituitary is modulated by intermittent hypoxia, cold and restraint.

Hypocretin in locus coeruleus and dorsal raphe nucleus mediates inescapable footshock stimulation (IFS)-induced REM sleep alteration

Corticosterone Combined with Intramedial Prefrontal Cortex Infusion of SCH 23390 Impairs the Strong Fear Response in High-Fear-reactivity Rats.

Regulation of hypoxia-induced release of corticotropin-releasing factor in the rat hypothalamus by norepinephrine.

Central amygdala CRF+ neurons promote heightened threat reactivity following early life adversity in mice

Blocking Mineralocorticoid Receptors Prior to Retrieval Reduces Contextual Fear Memory in Mice

Role of corticotropin-releasing factor and its receptor in nociceptive modulation in the central nucleus of amygdala in rats.

Type 1 Corticotropin-Releasing Factor Receptor Differentially Modulates Neurotransmitter Levels in the Nucleus Accumbens of Juvenile versus Adult Rats

Intra-amygdala circuits of sleep disruption-induced anxiety in female mice